Ontology highlight
ABSTRACT: Background
There is large variability among lung squamous cell carcinoma patients in response to treatment with cisplatin based chemotherapy. LncRNA is potentially a new type of predictive marker that can identify subgroups of patients who benefit from chemotherapy and it will have great value for treatment guidance.Methods
Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples.Results
Compared with the PD samples, 953 lncRNAs were consis
SUBMITTER: Hou Z
PROVIDER: S-EPMC4176963 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature